193 related articles for article (PubMed ID: 28060723)
1. The effect of androgen receptor expression on clinical characterization of metastatic breast cancer.
Kim JY; Park K; Lee E; Jung HH; Ahn JS; Im YH; Park WY; Park YH
Oncotarget; 2017 Jan; 8(5):8693-8706. PubMed ID: 28060723
[TBL] [Abstract][Full Text] [Related]
2. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
Liu D
Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
[TBL] [Abstract][Full Text] [Related]
3. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
Vera-Badillo FE; Chang MC; Kuruzar G; Ocana A; Templeton AJ; Seruga B; Goldstein R; Bedard PL; Tannock IF; Amir E
J Clin Pathol; 2015 Oct; 68(10):839-43. PubMed ID: 26076967
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
Wenhui Z; Shuo L; Dabei T; Ying P; Zhipeng W; Lei Z; Xiaohui H; Jingshu G; Hongtao S; Qingyuan Z
Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
[TBL] [Abstract][Full Text] [Related]
6. Impact of triple negative phenotype on breast cancer prognosis.
Kaplan HG; Malmgren JA
Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
[TBL] [Abstract][Full Text] [Related]
7. The expression and prognostic role of EBP1 and relationship with AR in HER2+ breast cancer.
Liu J; Xu C; Xu D; Cao L; Xue H; Meng Q; Niu Y
Virchows Arch; 2020 Aug; 477(2):279-289. PubMed ID: 32086588
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers.
Micello D; Marando A; Sahnane N; Riva C; Capella C; Sessa F
Virchows Arch; 2010 Oct; 457(4):467-76. PubMed ID: 20809337
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers.
Witzel I; Graeser M; Karn T; Schmidt M; Wirtz R; Schütze D; Rausch A; Jänicke F; Milde-Langosch K; Müller V
J Cancer Res Clin Oncol; 2013 May; 139(5):809-16. PubMed ID: 23392859
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.
Adamczyk A; Niemiec J; Janecka A; Harazin-Lechowska A; Ambicka A; Grela-Wojewoda A; Domagała-Haduch M; Cedrych I; Majchrzyk K; Kruczak A; Ryś J; Jakubowicz J
Pol J Pathol; 2015 Jun; 66(2):133-41. PubMed ID: 26247526
[TBL] [Abstract][Full Text] [Related]
12. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
Cortesi L; De Matteis E; Cirilli C; Marcheselli L; Proietto M; Federico M
Tumori; 2012 Nov; 98(6):743-50. PubMed ID: 23389361
[TBL] [Abstract][Full Text] [Related]
13. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
[TBL] [Abstract][Full Text] [Related]
14. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
[TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.
Kensler KH; Poole EM; Heng YJ; Collins LC; Glass B; Beck AH; Hazra A; Rosner BA; Eliassen AH; Hankinson SE; Winer EP; Brown M; Tamimi RM
J Natl Cancer Inst; 2019 Jul; 111(7):700-708. PubMed ID: 30445651
[TBL] [Abstract][Full Text] [Related]
16. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
Liu D; Zhou K
Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
[TBL] [Abstract][Full Text] [Related]
17. Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution.
Chen R; Qarmali M; Siegal GP; Wei S
Mod Pathol; 2020 Dec; 33(12):2499-2506. PubMed ID: 32620918
[TBL] [Abstract][Full Text] [Related]
18. Expression of sarcosine metabolism-related proteins in estrogen receptor negative breast cancer according to the androgen receptor and HER-2 status.
Kim MJ; Jung WH; Koo JS
Int J Clin Exp Pathol; 2015; 8(7):7967-77. PubMed ID: 26339363
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
[TBL] [Abstract][Full Text] [Related]
20. Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.
Kurozumi S; Joseph C; Raafat S; Sonbul S; Kariri Y; Alsaeed S; Pigera M; Alsaleem M; Nolan CC; Johnston SJ; Aleskandarany MA; Ogden A; Fujii T; Shirabe K; Martin SG; Alshankyty I; Mongan NP; Ellis IO; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Jul; 176(1):63-73. PubMed ID: 30941650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
